{"id":"hepalean-heparin","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Osteoporosis (with long-term use)"}]},"_chembl":{"chemblId":"CHEMBL4650299","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Heparin is an anticoagulant that works by binding to and enhancing the activity of antithrombin III, a natural inhibitor of coagulation factors. This prevents the formation of thrombin and fibrin, thereby inhibiting clot formation. Hepalean, as an LMWH derivative, offers more predictable pharmacokinetics and longer half-life compared to unfractionated heparin.","oneSentence":"Hepalean is a low-molecular-weight heparin (LMWH) that inhibits blood coagulation by potentiating antithrombin III activity against factors Xa and IIa.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:47:28.386Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thromboembolism prophylaxis and treatment"},{"name":"Deep vein thrombosis prevention and treatment"},{"name":"Pulmonary embolism prevention and treatment"}]},"trialDetails":[{"nctId":"NCT01343381","phase":"PHASE4","title":"Comparison of Heparin Types; Efficacy and Safety","status":"COMPLETED","sponsor":"McMaster University","startDate":"2011-06","conditions":"Coronary Artery Disease","enrollment":21},{"nctId":"NCT00848796","phase":"NA","title":"Comparative Study of Two Brands of Heparin Already on the Market","status":"COMPLETED","sponsor":"Southlake Regional Health Centre","startDate":"2006-09","conditions":"Coronary Artery Bypass Grafting","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Hepalean Heparin","genericName":"Hepalean Heparin","companyName":"McMaster University","companyId":"mcmaster-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hepalean is a low-molecular-weight heparin (LMWH) that inhibits blood coagulation by potentiating antithrombin III activity against factors Xa and IIa. Used for Thromboembolism prophylaxis and treatment, Deep vein thrombosis prevention and treatment, Pulmonary embolism prevention and treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}